TABLE 3.
Study (yr) (reference) | No. of doses | Sample sizea | Age group | Test used | Timing of test (wk) | Seroconversion rate (%) |
---|---|---|---|---|---|---|
Weibel et al. (1984) (136) | 1 | 468 | Children | IAHA/FAMA | 8 | 94 |
Gershon et al. (1988) (58) | 1 | 184b | Adults | FAMA | 4, 8, and 12 | 82 |
2 | 150b | 94 | ||||
LaRussa et al. (1990) (89) | 1 | 33 | Children | FAMA | 6 | 91 |
White et al. (1991) (142) | 1 | 3,303 | Children and adolescents | gpELISA | 6 | 96c |
Clements et al. (1995) (28) | 1 | 426 | Children | ELISA/gpELISA | 6 | 95 |
Kuter et al. (1995) (84) | 1 | 490 | Adolescents and adults | gpELISA | 4 | 75 |
2 | 99 | |||||
Asano (1996) (6) | 1 | 2,330 | Children | IAHA | 4 | 92 |
Ngai et al. (1996) (109) | 1 | 1,731 | Children | gpELISA | 6 | 98d |
2 | 718 | 100 | ||||
Varis and Vesikari (1996) (130) | 1 | 325 | Children | FAMA | 5-9 | 99 |
Johnson et al. (1997) (76) | 1 | 292 | Children | FAMA | 6 | 96 |
Excluding seropositive individuals.
Subjects were tested after each dose of vaccine in a two-dose protocol (i.e., the sample populations overlap).
79% in the 13- to 17-year age group.
Only 86% of “seroconverters” to a single dose of vaccine achieved titers of 5 gpELISA units/ml or above (83).